Endocrine Abstracts

Background: Type 1 diabetes (T1D) is a metabolic disease of unknown aetiology that results from the autoimmune destruction of the insulin-producing pancreatic β-cells. Exogenous insulin administration is the only treatment for patients. Partial remission or “honeymoon phase” classically occurs a few weeks after insulin therapy has been initiated. During this stage the patient’s need for exogenous insulin can decline by 50%, and near-normal metabolic control...